Eris Lifesciences: Navigating Growth and Strategic Shifts in Q3 and 9M FY26

Eris Lifesciences Limited has presented a robust performance for the third quarter and nine months ended FY26, demonstrating resilience and strategic foresight in a dynamic pharmaceutical landscape. The company reported a consolidated revenue of Rs. 807 crore for Q3 FY26, marking an 11% year-on-year growth, and Rs. 2,373 crore for 9M FY26, an 8.4% increase. This growth was underpinned by strong operational efficiency, with consolidated EBITDA reaching Rs. 282 crore in Q3 (up 13% yoy) and Rs. 847 crore in 9M (up 11% yoy). Profit after Tax (PAT) also saw a significant boost, rising 25.1% to Rs. 109 crore in Q3 and 35.2% to Rs. 369 crore in 9M FY26, reflecting improved margins and reduced interest expenses.

The Domestic Branded Formulations (DBF) segment continues to be a cornerstone of Eris's success, recording a 10% year-on-year growth in both Q3 and 9M FY26. This performance is particularly noteworthy given the company's strategic decision to discontinue certain 'non-core' or 'tail-end' brands, primarily within general injectables. These brands were identified for their lack of alignment with core therapies, low profitability, and limited growth prospects. While this move is expected to have a ~2% impact on DBF revenue in FY27, it is anticipated to enhance absolute operating profits and overall operating profit margins by allowing Eris to focus on its high-growth, high-margin core portfolio. Excluding these discontinued brands, the core DBF portfolio clocked an impressive 12% growth in Q3 and 9M FY26 and is projected to deliver a 14% growth in FY26 with an EBITDA margin of approximately 39%.

Eris Lifesciences has made significant strides in the Insulins market, particularly following the Biocon acquisition. The company has successfully tripled its RHI Cartridges market share since the acquisition, achieving its stated objective of 25% market share in this segment. Overall, in the RHI + Glargine market, Eris has nearly doubled its market share from 9% to 16%, demonstrating strong traction and a clear switch from innovator brands. The company is poised for further expansion with the planned launch of Insulin Analogues like Aspart & Aspart Mix, Degludec, and Degludec+Liraglutide in FY27. Validation batches for these products are scheduled for March-April 2026, targeting the adjacent Rs. 1,750 crore market currently dominated by innovators. Furthermore, Eris's in-house insulin manufacturing facility at Bhopal is progressing, with RHI Vials already in production and Glargine Vials initiated in February 2026.

Strategic Product Launches and International Expansion

Beyond insulins, Eris is actively expanding its product portfolio with innovative launches. Esaxerenone, a next-generation nsMRA for hypertension, has been developed by Eris's in-house R&D team and is the first to launch in India. This product is approved for uncontrolled and resistant hypertension and has shown superior efficacy in lowering SBP and DBP compared to Eplerenone, positioning it as a potential game-changer in hypertension management. In the rapidly emerging GLP-1 market, Eris is well-prepared for the launch of Semaglutide. With a strategic partnership in place and final regulatory approval expected soon, the company's AMD site has completed process validation for form-fill-finish, ensuring adequate and scalable manufacturing capacity.

The International Business segment has also shown remarkable growth, with Q3 FY26 revenue surging 45% year-on-year to Rs. 111 crore, making it the strongest quarter yet. The 9M FY26 revenue reached Rs. 259 crore, an 11% year-on-year increase, aligning with management's guidance. While the segment experienced some margin compression due to significant upfront investments in people and EU CDMO capabilities, the full impact of these investments is expected to be realized starting FY27. Eris has strong visibility for its International Business, projecting revenues of Rs. 550-600 crore and EBITDA of Rs. 180-200 crore for FY27, with an ambitious target of Rs. 1,000 crore revenue by 2029/2030, driven significantly by CDMO and regulated markets.

Financial Health and Future Outlook

Eris Lifesciences continues to demonstrate strong financial discipline, particularly in debt reduction. The Net Debt to TTM EBITDA ratio has significantly decreased from approximately 4x to ~2x in FY25, with a reiterated guidance to achieve less than 1.5x by December 2026. The company has also maintained its total capex guidance of Rs. 750-800 crore over FY26-FY28, indicating a balanced approach to growth investments and financial prudence. The consolidated FY26 visibility includes a revenue target of approximately Rs. 3,200 crore (10% yoy growth) and an EBITDA of around Rs. 1,150 crore (14% yoy growth), with an EBITDA margin of 36%. This outlook underscores Eris's confidence in its strategic initiatives and operational capabilities to deliver sustained growth and enhanced shareholder value.